Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.

Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.

Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.

Abstract: Provided are compositions comprising a hydrogel formed from a cyclodextrin-modified branched polyethyleneimine and an adamantane-modified, eight-arm polyethyelene glycol. The hydrogel may contain an active agent, and can provide sustained release the active agent. Beneficial delivery characteristics may result from electrostatic or lipophilic interactions between the active agent and the hydrogel. Delivery of valproic acid from the present compositions can provide treatment following surgical resection of glioblastoma brain tumors.

Abstract: A method for preserving and stabilizing proteins includes the steps of forming an anhydrous medium having oily phase components having hydrophilic residues, and dispersing the proteins into the anhydrous medium under ambient pressure and temperature conditions so that the proteins are incorporated into the anhydrous medium so as to maintain an active formation of the proteins.

Abstract: Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

Abstract: Provided herein are GLP-1 agonist peptides conjugated with thyroid hormone receptor ligands that are capable of acting at the thyroid hormone receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes, obesity, metabolic syndrome and chronic cardiovascular disease, comprising administering the conjugates of the invention.

Abstract: The present invention provides a novel alkylating agent specifically binding to the genetic mutation site of a driver oncogene. There are provided are a complex formed by binding an alkylating agent to a pyrrole imidazole polyamide specifically binding to the genetic mutation site of a driver oncogene, a driver oncogene mutation-specific alkylating agent comprising the aforementioned complex, and a pharmaceutical composition comprising the aforementioned complex.

Abstract: In one aspect, the present disclosure provides a compound of the formula: In another aspect, the present disclosure also provides methods of preparing the compound disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compound disclosed herein. Additionally, methods of treating cancer with the compound disclosed herein are described.

Abstract: The present disclosure, relates, in general to methods for treating solid tumors comprising administering a drug-linker-antibody conjugate, wherein the drug is a tubulin disrupting agent.

Abstract: The invention provides, inter alia, methods of treating a disorder characterized by pathological activity of CD30+ cells, such as in certain solid, hematological and lymphoid cancers, in a non-adult human subject by administering an effective amount of an anti-CD30 ADC (antibody drug conjugate), such as, brentuximab vedotin, to the subject. The invention also provides corresponding kits and articles of manufacture suitable for performing the methods provided by the invention.

Abstract: The present invention provides a method for removing cysteine caps from antibodies and re-capping the antibodies with cysteine molecules. The methods include, inter alia, culturing a host cell comprising a protein molecule having at least one capped engineered cysteine residue, and contacting the cell culture with cystine. Dissolved oxygen levels can be manipulated in the cell culture to further enhance the removal and re-capping process.

Abstract: Provided herein, inter alia, are methods and compounds for targeted autophagy.

Abstract: A composition for gene therapy or transfection includes nucleic acid, natural polyphenol, and cationic molecules. There are several phenolic hydroxyl groups in the natural polyphenol, so as to eliminate free radicals, prevent cancer, fight inflammation, and provide antioxidants feature. Compared with the delivery of cationic molecules alone, the composition can significantly improve the transfection efficiency by about 60-70%, reduce the dose of effective transfection of cationic molecules by about 20 times, thereby reducing the toxicity of transfection and showing better organism compatibility. The composition of the present invention does not introduce other chemical reagents, does not require synthesis, has high biosafety, and can efficiently and safely deliver a plurality of nucleic acid molecules into cells. The composition can be used as a highly effective and low-toxicity nucleic acid drug in the treatment of gene-related diseases, and has good medicinal value.

Abstract: Compositions and methods for mitochondria genome editing are provided. Also provided are methods for treating mitochondrial disorders by the disclosed compositions.

Abstract: The invention relates to synthetic polynucleotides encoding fukutin related protein (FKRP). The invention further relates to nucleic acid constructs comprising the synthetic polynucleotides and methods of using these synthetic polynucleotides to treat dystroglycanopathy disorders.

Abstract: Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP).

Abstract: Provided herein are methods and compositions related to the in vivo testing of therapeutic agents comprising a human Fc in genetically modified rodents (e.g., the testing of the pharmacokinetic and/or pharmacodynamic properties of such a therapeutic agent in genetically modified rodents). In some embodiments the genetically modified rodents express antibodies comprising a human Fc (e.g., a human IgG1 Fc, a human IgG4 Fc). In some embodiments, the rodents express fully human antibodies (i.e., antibodies having human heavy chains and human light (? or ?) chains). In certain embodiments the genetically modified rodents comprise one or more Fc receptors with a human extracellular domain (e.g., a Neonatal Fc Receptor (FcRn), a ?-2-microglobulin polypeptide (?2M), a Fc ? receptor 1? (Fc?R1?), a Fc ? receptor 1 alpha (Fc?R1a), a Fc gamma receptor 2a (Fc?R2a), a Fc gamma receptor 2b (Fc?R2b), a Fc gamma receptor 3a (Fc?R3a), a Fc gamma receptor 3b (Fc?R3b), a Fc gamma receptor 2c (Fc?R2c)).

Abstract: The present disclosure features a condensation reaction and a luciferin-unmasking reaction that can be carried out under physiological conditions. In general, the condensation reaction involves reacting a bicyclic reactant with an aminothiol derivative, generating a luciferin or luciferin derivative. A luciferin can provide detectable luminescence. A luciferin derivative can be unmasked to provide detectable luminescence in a luciferin-unmasking reaction. The present disclosure provides bicyclic reactants and aminothiol derivatives suitable for use in the condensation reaction. The condensation and luciferin-unmasking reactions find use in a variety of applications, which are also provided.

Abstract: Embodiments of the present disclosure pertain to methods of opening a lipid bilayer by associating the lipid bilayer with a molecule that includes a moving component capable of moving (e.g., rotating) in response to an external stimulus; and exposing the molecule to an external stimulus before, during or after associating the molecule with the lipid bilayer. The exposing causes the moving component of the molecule to move and thereby open the lipid bilayer (e.g., by pore formation). The external stimuli may include an energy source, such as ultraviolet light. The opened lipid bilayer may be a component of cell membranes in vitro or in vivo. The opening of the lipid bilayer may allow for the passage of various materials (e.g., active agents, such as peptide-based drugs) through the lipid bilayer and into cells. Additional embodiments of the present disclosure pertain to the aforementioned molecules for opening lipid bilayers.

Abstract: The invention, in some aspects, relates to dummy-fluorescent (DF) polypeptide molecules and their encoding nucleic acid molecules and use of such molecules in fusion proteins and their encoding nucleic acid molecules. Compositions of the invention may be delivered to cells and subjects and used in methods to modulate electrical activity of cells in which they are expressed, and for treatment of diseases and conditions in subjects.

Abstract: Dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and ?* acceptor group-containing dioxetane based chemiluminescence probes can be included in compositions. The chemiluminescence probes are useful for both diagnostics and in vivo imaging.

Abstract: The present invention generally relates to methods and system for the synthesis of imaging agents, and precursors thereof. The methods may exhibit improved yields and may allow for the large-scale synthesis of imaging agents, including imaging agents comprising a radioisotope (e.g., 18F). Various embodiments of the invention may be useful as sensors, diagnostic tools, and the like. In some cases, methods for evaluating perfusion, including myocardial perfusion, are provided. Synthetic methods of the invention have also been incorporated into an automated synthesis unit to prepare and purify imaging agents that comprise a radioisotope. In some embodiments, the present invention provides a novel methods and systems comprising imaging agent 1, including methods of imaging in a subject comprising administering a composition comprising imaging agent 1 to a subject by injection, infusion, or any other known method, and imaging the area of the subject wherein the event of interest is located.

Abstract: Provided is a process of producing activated particles comprising 188Re-isotopes and/or 186Re-isotopes by irradiating non-volatile and water-insoluble starting particles comprising a rhenium compound with neutrons. Further provided is a process of producing corresponding non-volatile and water-insoluble starting particles. Further provided are respective starting particles and activated particles, respectively, and a composition comprising a plurality of activated particles. The activated particles, and the composition comprising same are suitable for use in radionuclide therapy, and for cosmetic applications.

Abstract: The present invention includes a device cleaner, and method of use, for cleaning a device port, particularly a medical device port, that may be inserted into the device port cleaner for cleaning and/or disinfecting.

Abstract: Methods and systems for a catheter access port cleaning, disinfection or sterilization device are disclosed. The catheter access port cleaning, disinfection or sterilization device may comprise, a first housing having a power source and control circuit; a second housing shaped to mate with a catheter and having a first ultra-violet light source mounted therein, the first housing wired to the second housing to power the light source. When activated, the ultra-violet light source emits ultra-violet radiation that is transmitted from the second housing to the catheter attached to a patient. In this way, the device provides an efficient system for cleaning, disinfecting or sterilizing an access port in the second housing while reducing patient infections.

Abstract: This present invention generally relates to a process for manipulating the chemistry of a product using high voltage atmospheric cold plasma (HVACP) in the presence of a working gas, and in particular to a process for inactivating pathogenic microorganisms in a liquid product by adding an acidic component to or adjusting an acidic component of a product in combination with HVACP treatment. A product of this process is also in the scope of this disclosure.

Abstract: SYSTEM, METHOD AND PROCESS FOR DISINFECTION OF INTERNAL SURFACES IN ASEPTIC TANKS AND PIPELINES BY FLOODING WITH SANITIZING FOG in facilities designed to store liquids in general, such system comprising an external equipment with means to generate sanitizing fog, controlling means of gases flow rate, in-line detectors and draining means of gases inside the tank, input means of fog carrying means comprising inert gases. Disinfection process comprises introduction of a sanitizing fog with droplets with a maximum size of 10 ?m, preferably with maximum size of 5 ?m, simultaneously with removal of gases enclosed inside such tanks and pipelines, maintaining a positive pressure inside such tanks and pipelines, such method providing reduction of oxygen concentration inside the tanks in two steps, the first one comprising reduction to near 10% and the second a reduction to a value below 1%, filling the tank with a sanitizing fog during the second step.

Abstract: In an example, a light control system includes a power converter, a light source, a sensor, and a control device. The power converter can convert an input power received from a power source to a supply power, and includes a power factor corrector (PFC) configured to adjustably control an electrical parameter of the supply power. The light source can, using the supply power, emit light at an intensity related to the electrical parameter. The sensor can sense a condition related to operation of the light source. The control device is communicatively coupled to the PFC and the sensor, and configured to: (i) receive, from the sensor, a sensor signal indicating an input parameter related to the condition, and (ii) based on sensor signal, provide a feedback signal to the PFC to cause the PFC to adjust, based on the input parameter, the electrical parameter of the supply power.

Abstract: In an example, a power factor corrector (PFC) including a first PFC input, a second PFC input, and a PFC output. The first PFC input is configured to receive an input power from a power source. The second PFC input is configured to receive a signal from a feedback circuit. The PFC output configured to output a direct current (DC) power, which is based on the input power at the first PFC input and the signal at the second PFC input. The feedback circuit is coupled to the PFC output and the second PFC input. The feedback circuit is configured to provide the signal at the second PFC input based on an input parameter related to a condition that is sensible by a sensor. The condition is related to operation of a load.

Abstract: Aspects of the present disclosure relate to a system including an image capture device and a computing device configured to receive a test image from the image capture device corresponding to a first surgical instrument, determine an identity type of the first surgical instrument using the test image in a machine vision technique, determine whether the first surgical instrument is flagged, and perform at least one operation in response to whether the first surgical instrument is flagged.

Abstract: A modular, integrated, combination air purification and aroma diffuser includes a UV and catalytic oxidation germicidal cell and multiple filtrations as pre-treatment of air diffusing essential oils or other liquids as ultra-fine droplets entrained in airflow into enclosed, habitable spaces. Liquid microbicide, insecticide, fumigant, or aroma therapy is kept cleaner by eradication of microbes. Comparatively larger droplets are separated out and recycled to the reservoir after initial atomization. An electrical module, between a purifier and filters upstream and a diffuser downstream, includes a pump, a fan, and a controller for both. Staged, double-eduction, triple-separation processes include a micro-cyclone for quiet, well diffused flow of ultra-fine droplets.

Abstract: A reservoir containing an essential oil feeds to an eductor injecting a jet forming a plume of air entraining oil droplets. A series of drift chambers act as velocity reducers to alternately slow the flow droplets with entry, and then reaccelerate them upon exit through an exit channel. A micro cyclone separator operates between at least two of the drift chambers, exposing the flow to circumferential direction and centripetal acceleration driving comparatively larger droplets out of the flow away from comparatively finer droplets sufficiently small to remain with the flow of air. Separation of comparatively larger droplets, effectively eliminates “spitting” of liquids that might or rapid drift onto surrounding surfaces.

Abstract: The invention relates to a pharmaceutical composition and in particular a dermal patch or wound dressing comprising an acid-hydrolyzing oligomer and/or polymer and an acid-activated prodrug such that the active principle in the pharmaceutical composition or in the dermal patch or wound dressing is formed A from the prodrug under the effect of acid. The invention further relates to a corresponding method for releasing active principles from a pharmaceutical composition.

Abstract: The present invention relates to a polymer having a first monomer selected from the group consisting of: styrene, MMA, HEMA or MEMA and a second monomer selected from the group consisting of: GMA, DEAEA, DEAEMA, DMAA, BAEMA, 4-vinylpyridine, DMVBA, 1-vinylimidazole, DMAEA or a combination thereof as coating agent for a scaffold or a medical device, to promote cellular adhesion and/or cell growth or for the manufacture of yarns or threads. The polymer may further contain a third monomer selected from the group consisting of: BMA, DEGMEMA, DAAA and MMA. The invention also relates to a scaffold, a medical device, a yarn, a thread or a textile coated or manufactured with the polymers of the invention and relative methods.

Abstract: Methods and devices are described for using a controlled extensional strain to organize prefibrillar collagen and/or elastin solutions into an organized array of fibrils. The organized array of collagen fibrils produced by the disclosed methods and devices can be used for tissue engineering applications.

Abstract: Provided herein are tissue grafts, and in particular human placenta-derived tissue grafts and methods and articles for the manufacture and use thereof.

Abstract: Methods are disclosed for fabricating a three-dimensional engineered blood retinal barrier (BRB) comprising a choroid and retinal pigment epithelial cells. The methods include the use of bioprinting. Also disclosed is a three-dimensional engineered BRB, and its use. Methods are also disclosed for using the three-dimensional engineered BRB, such as for the treatment of retinal degeneration in a subject or screening. A three-dimensional printing insert that is adapted for bioprinting on a culture substrate sheet that is securely retained within and exposed through a printing frame is also disclosed.

Abstract: Provided herein are biocompatible hydrogel polymers capable of gelling in vivo comprising a therapeutic agent such as a protein or other biomolecule and kits comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and at least one therapeutic agent. The biocompatible hydrogel polymer is bioabsorbable and releases the therapeutic agent at a target site, avoiding systemic exposure and achieving a controlled delivery.

Abstract: The present invention discloses a method for preventing retraction of aqueous drops on a hydrophobic surface. The present invention also discloses a medical device coated with a hydrophilic coating comprising a substrate and a coating composition.

Abstract: Hygienic Hydrophilic coatings, hydrophilic coating formulations and wetting fluids that include an anti-infective agent.

Abstract: To provide a novel stent which is excellent in cell adhesive property and the like. A stent carrying a ceramic particle, wherein: the ceramic particle has a particle diameter within a range of 10 nm to 700 nm; the ceramic particle is a calcium phosphate sintered body particle; and the ceramic particle contains no calcium carbonate.

Abstract: Object of the present invention is to provide a safe sol for submucosal local injection which gels and creates a mucosal elevation having a high retention rate of mucosal elevation height when locally injected into a digestive submucosa. Provided is a sol for submucosal local injection containing from 0.2 mass % to 1.2 mass % of a collagen, water, a buffer, and from 200 mM to 420 mM sodium chloride.

Abstract: This invention is directed to a new method of mass-transfer/fabrication of micro-sized features/structures onto the inner diameter (ID) surface of a stent. This new approach is provided by technique of through mask electrical micro-machining. One embodiment discloses an application of electrical micro-machining to the ID of a stent using a customized electrode configured specifically for machining micro-sized features/structures.

Abstract: A new class of rapamycin 40-O-cyclic hydrocarbon esters is disclosed. The 40-O position of the rapamycin ester has the form 40-O—R, where R is C(O)—(CH2)n—X, n is 0, 1 or 2, and X is a cyclic hydrocarbon having 3-8 carbons, optionally containing one or more unsaturated bonds, and one or more linear (CH2)n) and/or cyclic (X) carbon atoms may have an OH or halide group. Also disclosed are therapeutic compositions and methods that employ the novel analogs.

Abstract: A handheld tool for providing irrigation and/or suction is provided. In certain embodiments, the tool has a single cannula for providing both suction and irrigation, while in others there are separate suction and irrigation cannulas. In some embodiments, flush water is supplied by actuating a flush button which both pinches closed a suction hose and opens a flush hose. If present, the irrigation cannula may be opened by actuating an irrigation button. In certain embodiments, the irrigation and/or flush button may be provided with blade tips to pinch closed the irrigation or flush hoses in cooperation with a blade extending from the tool housing.

Abstract: A medical suction & irrigation system used for removing bodily fluid and debris from a surgical site and particularly a hand-held medical device that utilizes suction tips and suction/irrigation tips during medical procedures. The system features use of a fully disposable suction and irrigation devices. This system comprises a series of devices which includes a universal handle member, interchangeable tip members, a storage member, and a receptacle member. This system will improve the workflow of users at all skill levels while integrating seamlessly into existing common practice. It is a fully integrated and optimized system which recognizes and utilizes the interaction between two distinct user groups with the overall benefit of reducing procedural times and increasing patient safety.

Abstract: Systems, apparatuses, and methods for instilling fluid to a tissue site in a negative-pressure therapy environment are described. Illustrative embodiments may include a pneumatically-actuated instillation pump that can draw a solution from a solution source during a negative-pressure interval, and instill the solution to a dressing during a venting interval. A pneumatic actuator may be mechanically coupled to a disposable distribution system that can provide a fluid path between the solution source and a distribution component. A bacterial filter may be disposed in the fluid path between the actuator and the distribution component to prevent contamination of the actuator during operation. The distribution system may be separated from the actuator and disposed of after operation, and the actuator may be re-used.

Abstract: Systems and methods are provided for separating a red blood cell-containing fluid into separated red blood cells and another fluid constituent. A suitable system includes a disposable fluid flow circuit and a durable, reusable separation system, with the circuit being mounted onto or otherwise associated with the separation system. The circuit includes a membrane separator for separating the fluid into its constituent parts, as well as a leukoreduction filter. The leukoreduction filter may be used before or after the red blood cell-containing fluid has been passed into the membrane separator. The red blood cell-containing fluid (if the leukoreduction filter is positioned upstream of the membrane separator) or the separated red blood cells (if the leukoreduction filter is positioned downstream of the membrane separator) may also be passed through a microaggregate filter prior to passing through the leukoreduction filter.

Abstract: A device, system and method for characterizing a chest drainage apparatus. The device includes a source of both positive pressure and negative pressure, a conduit to provide the positive pressure and the negative pressure to the chest drainage apparatus and a sensor to detect a response of said chest drainage apparatus to either said positive pressure or said negative pressure. The system includes a device that controllably provides either a positive pressure or a negative pressure to the chest drainage apparatus and a sensor to record the effect of the positive pressure or the negative pressure to the drainage apparatus. The method includes the steps of (1) providing a source of both positive pressure and negative pressure; (2) controllably applying either the positive pressure or the negative pressure to the chest drainage apparatus; and (3) detecting a response from the chest drainage apparatus to the pressure application.